Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $37.26.

According to TipRanks, Tenthoff is a 3-star analyst with an average return of 2.0% and a 36.57% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cue Biopharma, and Moderna.

Currently, the analyst consensus on Arvinas Holding Company is a Strong Buy with an average price target of $66.92, a 79.60% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $87.00 price target.

The company has a one-year high of $53.08 and a one-year low of $13.57. Currently, Arvinas Holding Company has an average volume of 745.6K.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arvinas Holding Company (ARVN) Company Description:

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.